Vanguard Group Inc. Acquires 10,119 Shares of Haemonetics Co. (NYSE:HAE)

Vanguard Group Inc. boosted its stake in Haemonetics Co. (NYSE:HAE - Free Report) by 0.2% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 5,179,388 shares of the medical instruments supplier's stock after purchasing an additional 10,119 shares during the quarter. Vanguard Group Inc. owned about 10.31% of Haemonetics worth $404,407,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in HAE. KLP Kapitalforvaltning AS purchased a new stake in shares of Haemonetics in the fourth quarter worth about $789,000. Quantbot Technologies LP purchased a new stake in shares of Haemonetics during the 4th quarter worth approximately $345,000. Kiker Wealth Management LLC bought a new position in shares of Haemonetics during the 4th quarter valued at approximately $1,234,000. Whittier Trust Co. purchased a new position in shares of Haemonetics in the fourth quarter valued at $62,000. Finally, Xponance Inc. increased its position in Haemonetics by 5.9% in the fourth quarter. Xponance Inc. now owns 7,246 shares of the medical instruments supplier's stock worth $566,000 after purchasing an additional 404 shares during the last quarter. Institutional investors own 99.67% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have commented on HAE. Barrington Research lowered their price objective on shares of Haemonetics from $108.00 to $95.00 and set an "outperform" rating for the company in a research report on Friday, February 7th. StockNews.com lowered Haemonetics from a "buy" rating to a "hold" rating in a research report on Saturday, February 15th. Raymond James reissued a "strong-buy" rating and set a $115.00 price objective (down from $120.00) on shares of Haemonetics in a research note on Friday, February 7th. Needham & Company LLC lowered their price objective on Haemonetics from $108.00 to $104.00 and set a "buy" rating for the company in a research note on Tuesday, March 18th. Finally, Bank of America downgraded Haemonetics from a "neutral" rating to an "underperform" rating and cut their target price for the company from $95.00 to $68.00 in a research report on Friday, February 7th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Haemonetics currently has an average rating of "Moderate Buy" and a consensus target price of $101.22.

Remove Ads

Haemonetics Trading Down 3.2 %

Shares of HAE stock traded down $1.92 on Monday, reaching $58.96. 1,063,855 shares of the company's stock were exchanged, compared to its average volume of 673,545. The company's fifty day simple moving average is $64.76 and its 200 day simple moving average is $74.13. The stock has a market capitalization of $2.96 billion, a PE ratio of 23.21, a P/E/G ratio of 1.11 and a beta of 0.41. The company has a current ratio of 3.97, a quick ratio of 2.55 and a debt-to-equity ratio of 1.35. Haemonetics Co. has a 52 week low of $58.24 and a 52 week high of $97.97.

Haemonetics (NYSE:HAE - Get Free Report) last issued its earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 EPS for the quarter, missing analysts' consensus estimates of $1.20 by ($0.01). Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. As a group, analysts forecast that Haemonetics Co. will post 4.55 EPS for the current year.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.